IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy.
J Immunol
; 176(10): 6347-55, 2006 May 15.
Article
em En
| MEDLINE
| ID: mdl-16670347
ABSTRACT
Tumor cell apoptosis is the basis of many cancer therapies, and tumor-specific T cells are the principal effectors of successful anti-tumor immunotherapies. In this study, we show that induction of tumor cell apoptosis by agonistic mAb against DR5, combined with delayed IL-21 treatment, suppressed tumor growth and pre-established tumor metastases. Synergistic effects of the combination were observed in several tumor models where the target tumor was sensitive to DR5-mediated apoptosis. IL-21 promoted tumor-specific CTL activity and enhanced memory responses to tumor rechallenge. These results indicate that a rational combination of Ab-based therapy that causes tumor cell apoptosis and a cytokine that promotes T cell memory is a useful new strategy for cancer immunotherapy.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ativação Linfocitária
/
Linfócitos T Citotóxicos
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Receptores do Fator de Necrose Tumoral
/
Citotoxicidade Imunológica
Tipo de estudo:
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
J Immunol
Ano de publicação:
2006
Tipo de documento:
Article
País de afiliação:
Austrália